文献速递炎症性肠病消化内镜

克罗恩病术后疾病复发的无创评估:代表意大利炎症性肠病组的多中心前瞻性队列研究

Noninvasive Assessment of Postoperative Disease Recurrence in Crohn's Disease: A Multicenter, Prospective Cohort Study on Behalf of the Italian Group for Inflammatory Bowel Disease.
PubMed 文献 · Clin Gastroenterol Hepatol · 2022-12-12

在3个意大利转诊中心前瞻性纳入91例克罗恩病回盲部切除术后患者,评估肠超声联合粪便钙卫蛋白无创检测术后复发的诊断准确性,以Rutgeerts评分≥2为参考标准。66%患者出现内镜复发,肠壁厚度每增加1 mm、肠系膜淋巴结存在及粪便钙卫蛋白≥50 mcg/g为独立预测因素。联合超声与粪便钙卫蛋白的无创方法可较有把握地检测术后复发,无需结肠镜检查。

要点

  • 肠壁厚度每增1 mm、肠系膜淋巴结存在及粪便钙卫蛋白≥50 mcg/g为内镜复发的独立预测因素。
  • 肠壁厚度≥3 mm且粪便钙卫蛋白≥50 mcg/g联合可正确分类75%患者,误判为复发者不足5%。
  • 肠壁厚度<3 mm且粪便钙卫蛋白<50 mcg/g联合可正确分类74%患者,误判为未复发者仅4.5%。

核心结论

  • 联合肠超声与粪便钙卫蛋白的无创方法可较有把握地用于检测克罗恩病患者的术后复发,无需结肠镜检查。

研究设计与样本

  • 多中心前瞻性队列研究,在3个意大利转诊中心连续纳入91例接受回盲部切除术的克罗恩病患者,术后1年内行结肠镜和肠超声检查。

主要发现

  • 91例患者中60例(66%)出现内镜复发。
  • 多变量分析显示,肠壁厚度每增加1 mm的比值比(OR)为2.43(95%CI 1.21-4.89,P=0.012),肠系膜淋巴结存在的OR为15.63(95%CI 1.48-164.54,P=0.022),粪便钙卫蛋白≥50 mcg/g的OR为8.58(95%CI 2.45-29.99,P<0.001),均为内镜复发的独立预测因素。
  • 存在淋巴结或肠壁厚度≥3 mm联合粪便钙卫蛋白≥50 mcg/g分别正确分类56%和75%的患者,误判为内镜复发者不足5%。
  • 肠壁厚度<3 mm联合粪便钙卫蛋白<50 mcg/g正确分类74%的患者,误判为无内镜复发者仅4.5%。

关键数值与推荐

  • 以Rutgeerts评分≥2定义为内镜复发。
  • 肠壁厚度每增加1 mm的OR为2.43(95%CI 1.21-4.89,P=0.012)。
  • 肠系膜淋巴结存在的OR为15.63(95%CI 1.48-164.54,P=0.022)。
  • 粪便钙卫蛋白≥50 mcg/g的OR为8.58(95%CI 2.45-29.99,P<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Colonoscopy (CS) is the gold standard to assess postoperative recurrence (POR) in Crohn's disease (CD). However, CS is invasive and may be poorly tolerated by patients. The aim of this study was to prospectively assess the diagnostic accuracy of a noninvasive approach in detecting POR, using the endoscopic Rutgeerts' score (RS) as the reference standard. METHODS: Consecutive patients with CD who underwent ileo-cecal resection were prospectively enrolled in 3 referral Italian centers. Patients underwent CS and bowel ultrasound within 1 year of surgery. Uni- and multivariable analyses were used to assess the correlation between noninvasive parameters and endoscopic recurrence, defined by a RS ≥2. RESULTS: Ninety-one patients were enrolled. Sixty patients (66%) experienced endoscopic POR. The multivariable analysis identified bowel wall thickness (BWT) per 1-mm increase (odds ratio [OR], 2.43; 95% confidence interval [CI], 1.21-4.89; P = .012), the presence of mesenteric lymph nodes (OR, 15.63; 95% CI, 1.48-164.54; P = .022), and fecal calprotectin (FC) values ≥50 mcg/g (OR, 8.58; 95% CI, 2.45-29.99; P < .001) as independent predictors for endoscopic recurrence. The presence of lymph nodes or the combination of BWT ≥3 mm and FC values ≥50 mcg/g correctly classified 56% and 75% of patients, with less than 5% of patients falsely classified as having endoscopic recurrence. Conversely, the combination of BWT <3 mm and FC <50 mcg/g correctly classified 74% of patients with only 4.5% of patients falsely classified as not having endoscopic recurrence. CONCLUSIONS: A noninvasive approach combining bowel ultrasound and FC can be used with confidence for detecting POR in patients with CD without the requirement for CS.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Furfaro F, D'Amico F, Zilli A, et al. Noninvasive Assessment of Postoperative Disease Recurrence in Crohn's Disease: A Multicenter, Prospective Cohort Study on Behalf of the Italian Group for Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2022. PMID: 36521739. doi:10.1016/j.cgh.2022.11.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。